CCDC153 Activators
CCDC153 engage in a series of intracellular interactions that ultimately lead to the protein's activation through a common messenger, cyclic AMP (cAMP). Forskolin, by directly stimulating adenylate cyclase, elevates cAMP levels, which in turn activates protein kinase A (PKA). PKA serves as a pivotal kinase that can phosphorylate CCDC153, thereby modulating its activity. Similarly, Isoproterenol and Salbutamol, as beta-adrenergic agonists, and Terbutaline, specifically as a beta2-adrenergic agonist, also promote adenylate cyclase activity. This results in a cascade effect that begins with increased cAMP and culminates in PKA-mediated activation of CCDC153. Epinephrine, a well-known adrenaline compound, and Dopamine, a neurotransmitter, both bind to their respective receptors and follow the same adenylate cyclase-cAMP-PKA pathway, influencing CCDC153 activity.
In addition to stimulatory compounds, several chemicals act as inhibitors of phosphodiesterases, the enzymes responsible for cAMP breakdown. For instance, Rolipram, through its selective inhibition of phosphodiesterase 4 (PDE4), and IBMX, as a non-selective phosphodiesterase inhibitor, both prevent cAMP degradation, thereby sustaining its action and the subsequent PKA-mediated activation of CCDC153. Histamine, engaging H2 receptors, and Prostaglandin E2 (PGE2), alongside Prostaglandin E1 (PGE1), bind to their respective G-protein-coupled receptors, all leading to increased adenylate cyclase activity and hence, higher levels of cAMP. Furthermore, Cholera toxin permanently activates the Gs alpha subunit, resulting in a continuous activation of adenylate cyclase, which leads to an extended increase in cAMP and prolonged action on PKA, impacting the activity of CCDC153. Through these diverse yet convergent pathways, these chemicals ensure that CCDC153 is activated via phosphorylation, highlighting the intricate web of intracellular signaling that governs protein function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly activates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP levels can enhance the activity of CCDC153 by promoting the cAMP-dependent protein kinase A (PKA) pathway, which can phosphorylate and activate various proteins including those involved in ciliary function, where CCDC153 is implicated. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that stimulates the production of cAMP through the activation of adenylate cyclase. The increase in cAMP stimulates the PKA pathway, potentially leading to the phosphorylation of proteins related to the function of CCDC153. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which breaks down cAMP. By inhibiting PDE4, rolipram increases intracellular levels of cAMP, thereby activating the PKA pathway and potentially enhancing the activity of CCDC153 through phosphorylation mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX, or 3-Isobutyl-1-methylxanthine, is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. Elevated levels of cAMP as a result of IBMX treatment could activate the PKA pathway, which in turn might lead to the activation of CCDC153-associated functions. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine interacts with beta-adrenergic receptors, which can lead to the activation of adenylate cyclase and an increase in cAMP levels. This can activate PKA, which may phosphorylate targets involved in the functional regulation of CCDC153. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can bind to dopamine receptors that are coupled to G-proteins, leading to activation of adenylate cyclase and increased levels of cAMP. This elevation may activate PKA and subsequently promote the functional activation of CCDC153. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $92.00 $277.00 $969.00 | 7 | |
Histamine can stimulate H2 receptors, which are positively coupled to adenylate cyclase via Gs proteins, leading to an increase in intracellular cAMP and activation of the PKA pathway, potentially contributing to the activation of CCDC153. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Prostaglandin E2 can activate G-protein-coupled receptors that stimulate adenylate cyclase, increasing cAMP levels and thus activating PKA. PKA then potentially facilitates the activation of CCDC153 through phosphorylation. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $30.00 $142.00 | 16 | |
Prostaglandin E1 (PGE1) activates its G-protein-coupled receptor leading to increased cAMP levels, which may activate the PKA pathway and subsequently, CCDC153 through phosphorylation events. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol is a beta2-adrenergic agonist that can activate adenylate cyclase, resulting in increased cAMP levels and PKA activation. This can lead to the phosphorylation and activation of proteins associated with CCDC153 function. | ||||||